Cargando…

Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop

Current imaging for prostate cancer (PCa) had limitations for risk stratification and staging. Magnetic resonance imaging frequently underestimated lymph node metastasis while bone scintigraphy often had diagnostic dilemmas. Prostatic-specific membrane antigen (PSMA) positron emission tomography-com...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Manoj, Choudhury, Partha Sarathi, Rawal, Sudhir, Goel, Harish Chandra, Talwar, Vineet, Singh, Amitabh, Sahoo, Saroj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216727/
https://www.ncbi.nlm.nih.gov/pubmed/30505224
http://dx.doi.org/10.4103/wjnm.WJNM_79_17
_version_ 1783368301835976704
author Gupta, Manoj
Choudhury, Partha Sarathi
Rawal, Sudhir
Goel, Harish Chandra
Talwar, Vineet
Singh, Amitabh
Sahoo, Saroj Kumar
author_facet Gupta, Manoj
Choudhury, Partha Sarathi
Rawal, Sudhir
Goel, Harish Chandra
Talwar, Vineet
Singh, Amitabh
Sahoo, Saroj Kumar
author_sort Gupta, Manoj
collection PubMed
description Current imaging for prostate cancer (PCa) had limitations for risk stratification and staging. Magnetic resonance imaging frequently underestimated lymph node metastasis while bone scintigraphy often had diagnostic dilemmas. Prostatic-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) has been remarkable in PCa recurrence. Ninety-seven PSMA PET-CT scans were reanalyzed for tumor node metastases staging and risk stratification of lymph node and distant metastasis proportion. Histopathology of 23/97 patients was available as gold standard. Chi-square test was used for proportion comparison. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), overestimation, underestimation, and correct estimation of T and N stages were calculated. Kappa coefficient (κ) was derived for inter-rater agreement. Lymph node or distant metastasis detection on PSMA PET/CT increased significantly with increase in risk category. PSMA PET/CT sensitivity, specificity, PPV, and NPV for extraprostatic extension, seminal vesicle invasion, and lymph node metastases were 63.16%, 100%, 100%, 36.36%; 55%, 100%, 100%, 25%; and 65.62%, 99.31%, 87.50%, and 97.53%, respectively. Kappa coefficient showed substantial agreement between PSMA PET/CT and histopathological lymph node metastases (κ = 0.734); however, it was just in fair agreement (κ = 0.277) with T stage. PSMA PET/CT overestimated, underestimated, and correct estimated T and N stages in 8.71%, 39.13%, 52.17% and 8.71%, 4.35%, and 86.96% cases, respectively. PSMA PET/CT has potential for initial risk stratification with reasonable correct N stage estimation, however underestimates T stage. Hence, we concluded that PSMA PET/CT should be used as “ first-stop-shop” for staging and initial risk stratification of PCa with regional magnetic resonance imaging in surgically resectable cases.
format Online
Article
Text
id pubmed-6216727
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-62167272018-11-30 Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop Gupta, Manoj Choudhury, Partha Sarathi Rawal, Sudhir Goel, Harish Chandra Talwar, Vineet Singh, Amitabh Sahoo, Saroj Kumar World J Nucl Med Original Article Current imaging for prostate cancer (PCa) had limitations for risk stratification and staging. Magnetic resonance imaging frequently underestimated lymph node metastasis while bone scintigraphy often had diagnostic dilemmas. Prostatic-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) has been remarkable in PCa recurrence. Ninety-seven PSMA PET-CT scans were reanalyzed for tumor node metastases staging and risk stratification of lymph node and distant metastasis proportion. Histopathology of 23/97 patients was available as gold standard. Chi-square test was used for proportion comparison. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), overestimation, underestimation, and correct estimation of T and N stages were calculated. Kappa coefficient (κ) was derived for inter-rater agreement. Lymph node or distant metastasis detection on PSMA PET/CT increased significantly with increase in risk category. PSMA PET/CT sensitivity, specificity, PPV, and NPV for extraprostatic extension, seminal vesicle invasion, and lymph node metastases were 63.16%, 100%, 100%, 36.36%; 55%, 100%, 100%, 25%; and 65.62%, 99.31%, 87.50%, and 97.53%, respectively. Kappa coefficient showed substantial agreement between PSMA PET/CT and histopathological lymph node metastases (κ = 0.734); however, it was just in fair agreement (κ = 0.277) with T stage. PSMA PET/CT overestimated, underestimated, and correct estimated T and N stages in 8.71%, 39.13%, 52.17% and 8.71%, 4.35%, and 86.96% cases, respectively. PSMA PET/CT has potential for initial risk stratification with reasonable correct N stage estimation, however underestimates T stage. Hence, we concluded that PSMA PET/CT should be used as “ first-stop-shop” for staging and initial risk stratification of PCa with regional magnetic resonance imaging in surgically resectable cases. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6216727/ /pubmed/30505224 http://dx.doi.org/10.4103/wjnm.WJNM_79_17 Text en Copyright: © 2018 World Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Gupta, Manoj
Choudhury, Partha Sarathi
Rawal, Sudhir
Goel, Harish Chandra
Talwar, Vineet
Singh, Amitabh
Sahoo, Saroj Kumar
Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop
title Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop
title_full Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop
title_fullStr Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop
title_full_unstemmed Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop
title_short Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop
title_sort initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: a first-stop-shop
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216727/
https://www.ncbi.nlm.nih.gov/pubmed/30505224
http://dx.doi.org/10.4103/wjnm.WJNM_79_17
work_keys_str_mv AT guptamanoj initialriskstratificationandstaginginprostatecancerwithprostaticspecificmembraneantigenpositronemissiontomographycomputedtomographyafirststopshop
AT choudhuryparthasarathi initialriskstratificationandstaginginprostatecancerwithprostaticspecificmembraneantigenpositronemissiontomographycomputedtomographyafirststopshop
AT rawalsudhir initialriskstratificationandstaginginprostatecancerwithprostaticspecificmembraneantigenpositronemissiontomographycomputedtomographyafirststopshop
AT goelharishchandra initialriskstratificationandstaginginprostatecancerwithprostaticspecificmembraneantigenpositronemissiontomographycomputedtomographyafirststopshop
AT talwarvineet initialriskstratificationandstaginginprostatecancerwithprostaticspecificmembraneantigenpositronemissiontomographycomputedtomographyafirststopshop
AT singhamitabh initialriskstratificationandstaginginprostatecancerwithprostaticspecificmembraneantigenpositronemissiontomographycomputedtomographyafirststopshop
AT sahoosarojkumar initialriskstratificationandstaginginprostatecancerwithprostaticspecificmembraneantigenpositronemissiontomographycomputedtomographyafirststopshop